Neoadjuvant therapy with trastuzumab, paclitaxel and epirubicin for HER-2-positive operable breast cancer - Reply

被引：1
|
作者：
Buzdar, AU [1 ]
Theriault, RL [1 ]
Hunt, KK [1 ]
Hortobagyi, GN [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 30期
关键词：
D O I：
10.1200/JCO.2005.03.2797
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：7760 / 7761
页数：2
相关论文
共 50 条
  • [31] Trastuzumab-Based Neoadjuvant Therapy in Patients With HER2-Positive Breast Cancer
    Chang, Helena R.
    CANCER, 2010, 116 (12) : 2856 - 2867
  • [32] The efficacy of trastuzumab, pertuzumab, and docetaxel in patients with HER-2-positive metastatic breast cancer
    Liem, Jean A.
    Kurniawan, Andree
    Christiano, Joysya
    Argo, Teresa M.
    Law, Natasha K.
    Asafia, Darlene
    ANNALS OF ONCOLOGY, 2022, 33 : S538 - S538
  • [33] Trastuzumab emtansine in the systemic treatment of HER-2-positive breast cancer brain metastases
    Frenel, Jean-Sebastien
    Bally, Olivia
    Bourbouloux, Emmanuelle
    Berton-Rigaud, Dominique
    Campone, Mario
    Bachelot, Thomas
    Heudel, Pierre-Etienne
    BULLETIN DU CANCER, 2016, 103 (05) : 507 - 510
  • [34] Alterations in mRNA profiles of trastuzumab-resistant Her-2-positive breast cancer
    Zhao, Bin
    Zhao, Yang
    Sun, Yan
    Niu, Haitao
    Sheng, Long
    Huang, Dongfang
    Li, Li
    MOLECULAR MEDICINE REPORTS, 2018, 18 (01) : 139 - 146
  • [35] Paclitaxel, Carboplatin, and Trastuzumab in a Neoadjuvant Regimen for HER2-Positive Breast Cancer: The TRAIN Study.
    Sonke, G. S.
    Mandjes, I. A.
    Holtkamp, M.
    Schot, M.
    Oosterkamp, H. M.
    Wesseling, J.
    Vrancken, Peeters M-J T.
    Rodenhuis, S.
    Linn, S. C.
    CANCER RESEARCH, 2011, 71
  • [36] A phase II trial of neoadjuvant epirubicin/cyclophosphamide followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer
    Kodera, A.
    Hirano, A.
    Inoue, H.
    Ogura, K.
    Hattori, A.
    Sakaguchi, S.
    Yukawa, H.
    Matsuoka, A.
    Tanaka, N.
    Kamimura, M.
    Jibiki, N.
    Fujibayasi, M.
    Naritaka, Y.
    Shimizu, T.
    CANCER RESEARCH, 2017, 77
  • [37] Comparison of the efficacy and survival analysis of neoadjuvant chemotherapy for Her-2-positive breast cancer
    Li, Si
    Wei, Wei
    Jiang, Yi
    Li, Qiuyun
    Huang, Qinghua
    Yang, Huawei
    Liu, Jianlun
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 3085 - 3093
  • [38] Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
    Romond, EH
    Perez, EA
    Bryant, J
    Suman, VJ
    Geyer, CE
    Davidson, NE
    Tan-Chiu, E
    Martino, S
    Paik, S
    Kaufman, PA
    Swain, SM
    Pisansky, TM
    Fehrenbacher, L
    Kutteh, LA
    Vogel, VG
    Visscher, DW
    Yothers, G
    Jenkins, RB
    Brown, AM
    Dakhil, SR
    Mamounas, EP
    Lingle, WL
    Klein, PM
    Ingle, JN
    Wolmark, N
    NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (16): : 1673 - 1684
  • [39] Clinical impact of interruption in adjuvant Trastuzumab therapy in patients with operable HER-2 positive breast cancer
    Sagar Sardesai
    Jasmine Sukumar
    Mahmoud Kassem
    Marilly Palettas
    Julie Stephens
    Evan Morgan
    Daniel Addison
    Ragavendra Baliga
    Daniel G. Stover
    Jeffrey VanDeusen
    Nicole Williams
    Mathew Cherian
    Maryam Lustberg
    Robert Wesolowski
    Bhuvaneswari Ramaswamy
    Cardio-Oncology, 6
  • [40] Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer
    Horiguchi, J.
    Koibuchi, Y.
    Rokutanda, N.
    Nagaoka, R.
    Kikuchi, M.
    Sato, A.
    Ishikawa, Y.
    Odawara, H.
    Iino, Y.
    Takeyoshi, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
12345